Atlas Trials

Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Clinical trial NCT04893941 · COMPLETED

Trial details

NCT number
NCT04893941
Sponsor
Keymed Biosciences Co.Ltd
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Moderate-to-severe Atopic Dermatitis
Start date
2020-07-21
Primary completion
2021-01-22
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.